MicroRNAs located in the Hox gene clusters are implicated in huntington\u27s disease pathogenesis by Hoss, Andrew G. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
University of Massachusetts Medical School Faculty Publications 
2014-02-27 
MicroRNAs located in the Hox gene clusters are implicated in 
huntington's disease pathogenesis 
Andrew G. Hoss 
Boston University School of Medicine 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/faculty_pubs 
 Part of the Genetics Commons, Molecular Genetics Commons, and the Nervous System Diseases 
Commons 
Repository Citation 
Hoss AG, Kartha VK, Dong X, Latourelle JC, Dumitriu A, Hadzi TC, Macdonald ME, Gusella JF, Akbarian S, 
Chen J, Weng Z, Myers RH. (2014). MicroRNAs located in the Hox gene clusters are implicated in 
huntington's disease pathogenesis. University of Massachusetts Medical School Faculty Publications. 
https://doi.org/10.1371/journal.pgen.1004188. Retrieved from https://escholarship.umassmed.edu/
faculty_pubs/418 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in University of 
Massachusetts Medical School Faculty Publications by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
MicroRNAs Located in the Hox Gene Clusters Are
Implicated in Huntington’s Disease Pathogenesis
Andrew G. Hoss1,2., Vinay K. Kartha1,3., Xianjun Dong4, Jeanne C. Latourelle1, Alexandra Dumitriu1,
Tiffany C. Hadzi1, Marcy E. MacDonald5, James F. Gusella5, Schahram Akbarian6, Jiang-Fan Chen1,
Zhiping Weng4, Richard H. Myers1,7*
1Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, United States of America, 2Graduate Program in Genetics and Genomics,
Boston University School of Medicine, Boston, Massachusetts, United States of America, 3 Bioinformatics Program, Boston University, Boston, Massachusetts, United States
of America, 4 Program in Bioinformatics and Integrative Biology, and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical
School, Worcester, Massachusetts, United States of America, 5Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston,
Massachusetts, United States of America, 6 Friedman Brain Institute, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, United States of
America, 7Genome Science Institute, Boston University School of Medicine, Boston, Massachusetts, United States of America
Abstract
Transcriptional dysregulation has long been recognized as central to the pathogenesis of Huntington’s disease (HD).
MicroRNAs (miRNAs) represent a major system of post-transcriptional regulation, by either preventing translational initiation
or by targeting transcripts for storage or for degradation. Using next-generation miRNA sequencing in prefrontal cortex
(Brodmann Area 9) of twelve HD and nine controls, we identified five miRNAs (miR-10b-5p, miR-196a-5p, miR-196b-5p, miR-
615-3p and miR-1247-5p) up-regulated in HD at genome-wide significance (FDR q-value,0.05). Three of these, miR-196a-
5p, miR-196b-5p and miR-615-3p, were expressed at near zero levels in control brains. Expression was verified for all five
miRNAs using reverse transcription quantitative PCR and all but miR-1247-5p were replicated in an independent sample
(8HD/8C). Ectopic miR-10b-5p expression in PC12 HTT-Q73 cells increased survival by MTT assay and cell viability staining
suggesting increased expression may be a protective response. All of the miRNAs but miR-1247-5p are located in intergenic
regions of Hox clusters. Total mRNA sequencing in the same samples identified fifteen of 55 genes within the Hox cluster
gene regions as differentially expressed in HD, and the Hox genes immediately adjacent to the four Hox cluster miRNAs as
up-regulated. Pathway analysis of mRNA targets of these miRNAs implicated functions for neuronal differentiation, neurite
outgrowth, cell death and survival. In regression models among the HD brains, huntingtin CAG repeat size, onset age and
age at death were independently found to be inversely related to miR-10b-5p levels. CAG repeat size and onset age were
independently inversely related to miR-196a-5p, onset age was inversely related to miR-196b-5p and age at death was
inversely related to miR-615-3p expression. These results suggest these Hox-related miRNAs may be involved in
neuroprotective response in HD. Recently, miRNAs have shown promise as biomarkers for human diseases and given their
relationship to disease expression, these miRNAs are biomarker candidates in HD.
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Introduction
Huntington’s disease (HD) (OMIM: 143100) is an inherited
neurodegenerative disorder characterized by involuntary move-
ment, dementia, and changes in personality. HD is transmitted as
an autosomal dominant disorder, for which an expansion of a
CAG trinucleotide repeat within the coding region of the
huntingtin gene (HTT) is the disease causing mutation [1]. The
CAG repeat codes for a polyglutamine domain in the Htt protein
and results in neuronal cell death predominantly affecting the
caudate nucleus and putamen although neuronal loss is wide-
spread in the HD brain [2,3]. While the biological processes
leading to neurodegeneration in HD are poorly understood,
transcriptional dysregulation has long been proposed as central to
the pathogenesis of HD. Widespread alterations in gene expression
have been reported [4] and several studies suggest that gene
expression may be altered at one or more of the stages of RNA
processing, translation, protein post-translational modification or
trafficking [5,6].
MicroRNAs (miRNAs) are small non-coding RNAs that
function as translational regulators of mRNA expression. miRNAs
may inhibit gene expression either by repressing translation, or by
targeting mRNA for either storage or degradation [7]. Recently,
dysregulation of miRNAs has been linked to neurological and
neurodegenerative disorders [8] and several studies have explored
the role of miRNAs in HD. Marti et al [9] performed miRNA-
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sequencing for two pooled HD samples and two pooled control
samples and reported altered expression for a large number of
miRNAs. Altered expression of miRNAs, quantified using
microarray technology, has been reported in cellular models of
HD [10–12] and in mouse models of HD [12–15] but a
comprehensive study of miRNA and mRNA expression obtained
through next-generation sequencing technology in human HD
samples has not been performed.
In order to investigate (1) the presence of altered miRNA
expression and (2) the potential role of miRNAs on the altered
mRNA expression seen in HD, we performed both miRNA-
sequencing and mRNA sequencing, using Illumina massively
parallel sequencing in twelve HD and nine neurologically normal
control brains. To our knowledge this is the first genome-wide
quantification of miRNA expression comparing human HD and
control brain, and the first to combine total miRNA expression
with total mRNA expression obtained through massively parallel
sequencing.
Results
Selection of prefrontal cortex and BA9
While the striatum is the region most heavily involved
neuropathologically in HD [3], 80% to 90% of the neurons in
that region will have degenerated by the time of death. These
changes, together with the presence of reactive astrocytosis, alter
the cellular composition of the striatum. In contrast, cortical
involvement in HD is well defined [2,16] and while it does not
experience dramatic neuronal degeneration, cortical neurons are
known to exhibit the effects of protein aggregation and nuclear
inclusion bodies characteristic of the disease. Therefore, we
selected the prefrontal cortex for these studies.
Five miRNAs are up-regulated in HD
After removing sample outliers using principal component
analysis filtering, we identified five out of 1,417 detected mature
miRNA species as differentially expressed between twelve HD and
nine control prefrontal cortex samples using the R statistical
package DESeq (Tables 1, 2 and 3; Figure 1). All five miRNAs
were significantly up-regulated in HD. The largest effect between
conditions was seen for miR-10b-5p, with a 28.41 fold increased
expression in HD relative to control samples (mean control
expression = 915.81; mean HD expression= 26,020.05, Figure 1).
miR-1247-5p was expressed at moderate levels in both control
(mean=49.44) and HD brain (mean= 102.01). Three of the
miRNAs, miR-196a-5p (mean control expression= 1.47; mean
HD expression = 27.49), miR-196b-5p (mean control expres-
sion= 2.49; mean HD expression= 11.01) and miR-615-3p (mean
control expression = 1.09, mean HD expression = 6.66), had near
zero expression levels in all nine control samples.
Validation and replication of miRNA findings
miRNA expression differences were orthogonally validated
using the Exiqon miRCURY LNA technology for reverse
transcription quantitative PCR (RT-qPCR) in eleven of twelve
sequenced HD samples and nine control samples originally studied
for miRNA-seq. All five miRNAs were confirmed to be
significantly up-regulated in HD (Table S1), consistent with our
miRNA-sequencing findings.
To replicate our findings in an independent sample set, we
performed RT-qPCR in an additional eight control and eight HD
prefrontal cortical samples (Tables S2 and S3). Four out of five
miRNA (miR-10b-5p, miR-196a-5p, miR-196b-5p, miR-615-3p)
were confirmed as significantly increased in expression in HD
(Table S4).
Similar proportion of neurons in HD and control cortical
brain homogenate samples
HD is characterized by progressive cortical atrophy, with
recognizable neuropathologic abnormalities in the neocortical gray
matter [2,16–20] (Table 1). To address whether miRNA
expression changes in HD may be due to altered ratios in brain
cell-type abundance, such as a change in the ratio of neurons to glial
cells, we compared the number of neuronal and non-neuronal
nuclei across conditions. Suspensions of cell nuclei of prefrontal
cortex from 28 HD cases and 19 controls were immunocytochem-
ically labeled with anti-NeuN, a neuron-specific nuclear antigen,
followed by flow cytometric analysis. The mean and range of
NeuN+ ratios for controls and cases were not significantly different
(t = 1.67, p-value= 0.10; Figure S1), suggesting cortical neuron loss
in the BA9 area in HD is relatively modest and does not account for
the dramatic alterations in miRNA levels reported here.
Increased miR-10b-5p expression is not observed in
Parkinson’s disease (PD)
To establish whether miR-10b-5p change is a generalized
response to neurodegeneration, we evaluated this miRNA in PD
prefrontal cortex. While cortical neuronal loss is variable in PD,
both PD and HD are neurodegenerative and caused by protein
inclusions. We selected PD prefrontal cortex samples that
exhibited reported neuron loss on their neuropathological
evaluation (n= 6) and PD samples without reported cortical
neuronal loss (n = 8). From total RNA, RT-qPCR was performed
for miR-10b-5p (Table S5). No difference was seen in miR-10b-
5p expression when stratifying PD based on the extent of neuron
loss (t = 0.59, p-value = 0.58). Additionally, no significant differ-
ence in HD miR-10b-5p expression from qPCR was observed
when stratifying HD cases based on a measure of cortical neuron
loss (f = 0.28, p-value = 0.76).
Next, the relative expression of miR-10b-5p in PD was
compared to all nineteen HD and eighteen control samples
Author Summary
Huntington’s disease (HD) is an inherited fatal neurological
disorder that commonly affects people in midlife. Past
studies have implicated abnormal patterns of gene
expression as a candidate for causing the death of the
brain cells affected in HD. MicroRNAs (miRNAs) are small
molecules that regulate and target transcripts for either
storage or destruction. We measured the levels of miRNAs,
as well as the levels of gene expression (mRNAs) in twelve
HD and nine control brain samples. We found five miRNAs
that had greatly increased expression in the HD brains,
including three that were not expressed in the normal
samples. Four of these were related to important
characteristics of the disease expression, including the
age at disease onset, and the age at death of the
individual. The genes that these miRNAs target for
regulation were also altered in their expression with most
being increased, suggesting they may have been targeted
for storage. One of the miRNAs, miR-196a-5p was
previously implicated in enhancing the survival of brain
cells in HD. When we overexpressed miR-10b-5p in an HD
cell model, the cells survived longer than untreated cells,
suggesting these miRNAs may promote neuron survival
and may hold new clues for treatments in HD.
MicroRNAs in Huntington’s Disease
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Figure 1. Differentially expressed miRNAs in Huntington’s disease. miR-10b-5p, miR-1247-5p, miR-196a-5p, miR-196b-5p, and miR-615-3p
were identified as differentially expressed in Huntington’s disease prefrontal cortex compared to non-neurological disease controls by Illumina
miRNA-sequencing. Normalized expression values quantified from DESeq analysis are shown on the y-axis. miR-196a-5p, miR-196b-5p and miR-615-
3p were essentially not expressed in control samples, while the mean HD expression was 27.49, 11.01 and 6.66 respectively. miR-1247-5p was
expressed at moderate levels in both control (mean= 49.44) and HD brain (mean= 102.01). miR-10b-5p was expressed in control (mean= 915.81) and
highly expressed in HD brain (mean= 26,020.05). For miRNA, *p,0.05 and ***p,0.001, as determined by DESeq, followed by the Benjamini-
Hochberg multiple comparison correction. (HD=Huntington’s disease).
doi:10.1371/journal.pgen.1004188.g001
Table 1. HD brain samples analyzed for mRNA-seq, miRNA-seq and RT-qPCR validation of miR-10b-5p.
Sample ID miRNA-seq RT-qPCR PMI (hr.) RIN or RQN Death age Onset age Duration (yr.) CAG repeat size
Neuron Loss in
Neocortical Gray Matter
HD-01 Passed Y 37 7.1 55 44 11 45 1
HD-02 Passed Y 6 7.5 69 63 6 41 1
HD-03 Passed Y 21 7 71 52 19 43 1
HD-05 Passed Y 19 6.9 48 25 23 48 2
HD-06 Passed Y NA 6.2 40 34 6 51 1
HD-07 Passed Y 8 8.5 72 55 17 41 1
HD-08 Passed Y 21 7.4 43 NA NA 49 1
HD-09 Passed Y 4 7.8 68 45 23 42 1
HD-10 Passed Y 6 8.3 59 35 24 46 1
HD-12 Passed Y 13 6 68 52 16 42 0
HD-13 Passed N 25 6.1 57 40 17 49 1
HD-14 Passed Y 11 7.3 48 38 10 45 1
Mean - - 15.48 7.18 58.17 43.91 15.64 45.17 0.875
All of the HD samples passed mRNA-seq QC.
Scale of neuron loss: 0 = absent, 1 =mild, 2 =moderate.
doi:10.1371/journal.pgen.1004188.t001
MicroRNAs in Huntington’s Disease
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assayed. While no significant difference in miR-10b-5p expression
was observed between control and PD samples (q = 0.05, p = 0.99),
a significant difference was seen in HD compared to PD (q= 7.30,
p,0.0001; Figure 2), suggesting increased miR-10b-5p expres-
sion, independent of neuron loss, is not a generalized response to
neurodegeneration.
Ectopic miR-10b-5p expression protects HD cell lines
from polyglutamine-mediated cytotoxicity
To determine the functional importance of miR-10b-5p up-
regulation in HD, we ectopically expressed miR-10b-5p in PC12
Q73 cells. These cell stably expressed huntingtin fragment derived
from exon 1 (1–90), contain a pathogenic, 73 long polyglutamine
repeat and a MYC epitope for protein identification. PC12 cells
have been shown to terminally differentiate and form neural
processes upon nerve growth factor (NGF) treatment [21], and
HD models of these cells have been highly characterized,
exhibiting phenotypic changes such as aggregate formation and
polyglutamine-dependent cell death [22–26].
PC12 Q73 cells were transfected with miR-10b-5p mimic or a
negative control mimic, cel-miR-67-3p, after 48 hours post-
differentiation. Cell survival was quantified using a MTT cell
viability assay 48 hours post-transfection. Increased survival,
though modest (53.9% versus 48.2%), was statistically higher for
cells transfected with miR-10b-5p compared to cells transfected
with negative control miRNA (q= 4.58, p-value,0.0001;
Figure 3). The enhanced survival via ectopic miR-10b-5p
expression was further substantiated in experiments using viable
fluorescent cell staining, where miR-10b-5p transfected cells
showed increased cell viability over cells transfected with negative
control miRNA (t = 2.381, p-value = 0.018).
Thus, miR-10b-5p may play a protective role in enhancing cell
survival during stress. To model stress, we treated miRNA
transfected cells with 1 uM MG 132, a potent proteasome
inhibitor that increases huntingtin aggregation and cellular
apoptosis in PC12 HD cell lines [27]. As expected, MG 132
treated cells had reduced cell viability as compared to untreated
cells (cel-miR-67-3p, q = 6.52, adjusted p-value,0.0001; miR-
10b-5p, q = 10.88, adjusted p-value,0.0001). However, MG 132
treated miR-10b-5p transfected PC12 Q73 cells exhibited
improved survival over those transfected with negative control
miRNA (q= 3.728, adjusted p-value = 0.045). No statistical
difference was observed when comparing miR-10b-5p levels with
MG 132 treatment to cel-miR-67-3p without treatment, (q = 2.95,
Table 2. Control brain samples analyzed for mRNA-seq,
miRNA-seq and RT-qPCR validation of miR-10b-5p.
Sample ID miRNA-seq RT-qPCR PMI (hr.) RIN or RQN Death age
C-14 Passed Y 21 8 79
C-21 Passed Y 26 7.3 76
C-29 Passed Y 13 6.4 93
C-31 Passed Y 24 7.3 53
C-32 Passed Y 24 8.3 57
C-33 Passed Y 15 7.5 43
C-35 Failed PCA N 21 7.6 46
C-36 Passed Y 17 7.5 40
C-37 Failed PCA N 28 8.3 44
C-38 Passed Y 20 7.7 57
C-39 Passed Y 15 7.3 80
Mean - - 20.36 7.49 60.73
All the control samples passed mRNA-seq QC.
RIN = RNA Integrity Number, RQN=RNA Quality Number.
PMI = Postmortem Interval.
doi:10.1371/journal.pgen.1004188.t002
Table 3. Differentially expressed miRNAs from miRNA-seq.
miRNA Control expression HD expression Fold Change p-value q-value*
miR-196a-5p 1.47 27.49 18.66 2.05E-10 2.91E-07
miR-10b-5p 915.81 26020.05 28.41 1.99E-08 1.41E-05
miR-615-3p 1.09 6.66 6.09 2.73E-05 1.29E-02
miR-1247-5p 49.44 102.01 2.06 7.67E-05 2.72E-02
miR-196b-5p 2.49 11.01 4.41 9.77E-05 2.77E-02
* FDR-adjusted q-value.
doi:10.1371/journal.pgen.1004188.t003
Figure 2. miR-10b-5p expression in control, Parkinson’s
disease and Huntington’s disease prefrontal cortex. Up-regula-
tion of miR-10b-5p was confirmed in HD by performing RT-qPCR,
comparing nineteen Huntington’s disease prefrontal cortex samples to
eighteen non-neurological disease control samples (***p,0.001) or
fourteen Parkinson’s disease samples (***p,0.001). DDCT values of miR-
10b-5p in PD and HD as compared to controls are shown on the y-axis.
The absence of up-regulation in PD frontal cortex suggests that up-
regulation of miR-10b-5p may be HD specific. (CT = cycle threshold; RT-
qPCR= reverse transcription quantitative PCR; PD= Parkinson’s disease;
HD=Huntington’s disease).
doi:10.1371/journal.pgen.1004188.g002
MicroRNAs in Huntington’s Disease
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adjusted p-value = 0.16), suggesting miR-10b-5p may enhance
survival in times of cellular stress.
miRNA expression is related to clinical variables in HD
RNA sequence count data may be non-normally distributed
[28], and tests of normality for miRNA expression levels in HD
found that miR-10b-5p was negatively skewed (see Materials
and Methods). Therefore, to test the relationship of miRNA
expression to clinical variables such as CAG repeat size, age at
onset of motor symptoms, disease duration and age at death, as
well as to the sample quality information for RIN/RQN (RNA
integrity number/RNA quality number), we applied a step-wise
backwards selection, negative binomial regression model.
Age at onset, duration and age at death are inter-dependent and
could not be simultaneously included in the models. Furthermore,
age at onset and age at death were strongly correlated with each
other (Pearson r = 0.85, p-value = 5e-04) and both were correlated
with CAG repeat size (r =20.84, p-value = 6e-04, and r =20.89,
p-value = 1e-04 respectively) while duration was not correlated
with age at onset, age at death or CAG repeat size in this sample.
To determine which variables best modeled the relationship of the
miRNAs to clinical variables, we compared the Akaike informa-
tion criterion (AIC) for each variable (onset age, death age and
duration) in regression analyses that adjusted for the effect of CAG
repeat size. Of these three variables, duration was found to have
the poorest fit with each of the five miRNAs and therefore we
report analyses containing age at onset and age at death.
Among the HD brains, CAG repeat size, age at onset and age at
death were all independently found to have a negative association
with miR-10b-5p (CAG, b=20.18, p-value= 2.7e-05; onset, b=2
0.05, p-value= 1.9e-05; death, b=20.07, p-value= 6.8e-07). CAG
repeat size and age at onset were found to be independently,
negatively related to miR-196a-5p (CAG, b=20.15, p-va-
lue= 1.7e-02; onset, b=20.07, p-value= 1.4e-03). Age at death
was significantly related to miR-615-3p expression (b=20.03, p-
value= 0.0045) and age at onset was associated with miR-196b-5p
(b=20.04, p-value= 9e-04). No association to any clinical features
was seen for miR-1247-5p. In order to fully evaluate whether there
was any effect of disease duration on the observed relationships to
the clinical features, duration was added back into final models. No
substantial changes to the effect estimates were observed with the
addition of duration to any of the models.
None of the miRNA levels was related to post-mortem interval
in either control or HD case samples. The essentially null level of
expression in controls prevented meaningful assessment of the
relationship of miR-196a-5p, miR-196b-5p and miR-615-3p with
Figure 3. miR-10b-5p overexpressing PC12 Q73 cells exhibit reduced cytotoxicity. PC12 cells expressing huntingtin exon 1 with a
polyglutamine expansion spanning 73 repeats were transfected with miR-10b-5p or cel-miR-67-3p as a negative control. On day 3 post-
differentiation, a subset of cells were treated with 1 uM MG 132. A MTT assay was used to measure cell viability after four days post differentiation. On
the Y-axis, the viability percentage was calculated from the initial cell count. Error bars represent SEM. (****p,0.0001; **p,0.001 *p,0.05).
doi:10.1371/journal.pgen.1004188.g003
MicroRNAs in Huntington’s Disease
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clinical variables, in particular age at death, or sample variables,
post-mortem interval (PMI), or RIN/RQN. Analysis of miR-10b-
5p showed no association to age at death (b=20.002, p-
value = 0.60), or PMI (b=20.014, p-value = 0.31), but did show
association with RIN/RQN (b=0.54, p-value = 7.2e-05) in
controls. miR-1247-5p showed association with later age at death
(b=20.013, p-value = 0.024) in controls.
Expression of miR-10b-5p, miR-196a-5p, miR-196b-5p
and miR-615-3p are correlated
Among the twelve HD samples, the levels of four out of the five
significantly differentially expressed miRNAs (miR-10b-5p, miR-
196a-5p, miR-196b-5p, miR-615-3p) were strongly correlated
with each other, (Spearman r range 0.71–0.88; p range 0.0002–
0.01). miR-1247-5p was not significantly correlated with these
miRNAs (Spearman r range 0.13–0.51; p range 0.09–0.70).
Because the values of miR-615-3p and miR-196a-5p were
essentially zero in the control samples, correlations among the
miRNAs were not performed for controls.
mRNA targets of miR-10b-5p, miR-196a-5p, miR-196b-5p
and miR-615-3p may have similar functions
Watson-Crick base-pairing between nucleotide position 2
through 8 on the mature miRNA, termed the ‘seed region,’ and
the 39 untranslated region (39 UTR) of target mRNA determine
the recognition, specificity and efficiency of miRNA silencing [29].
Seed sequences differ for miR-10b-5p (ACCCUGU), miR-615-3p
(CCGAGCC) and miR-1247-5p (CCCGUCC) suggesting these
miRNA have different targets, while miR-196a-5p and miR-196b-
5p share a seed sequence (AGGUAGU) and only differ by a single
base difference in mature miRNA sequence.
Targets of the five miRNAs were obtained from miRWalk
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html),
a repository of experimentally validated miRNA targets curated
from literature and online resources [30]. miRWalk targets of miR-
196a, miR-196b and miR-1247 were not strand specific. The
miRWalk database contained 84 unique targets for miR-10b-5p, 80
for miR-196a, 40 for miR-196b, two for miR-1247 and twelve for
miR-615-3p. Since miR-1247 had just two validated targets, it was
removed from analysis.
Four target genes (DICER1, HOXA7, HOXB4, HOXD1) were
shared across all four miRNAs. miR-10b-5p shared eleven targets
with miR-196a-5p (HOXB8, COX8A, HOXA10, NPC1, FLT3,
AKT1, NPM1, DROSHA, AGO2, NFYC, PAX7), and one with miR-
615-3p (MAPK8). miR-196a and miR-196b shared 28 targets. In
all, eleven of the 167 unique validated targets were Hox cluster
genes (HOXA1, HOXA7, HOXA9, HOXA10, HOXB4, HOXB7,
HOXB8, HOXC8, HOXD1, HOXD4, HOXD10).
To understand the influence these miRNAs may be having on
shared biological processes, targets of each miRNA were analyzed
using IPA Core Analysis. To find overlap in biological functions
and canonical pathways of each miRNA and its targets, the IPA
Core Comparison Analysis tool was used. After correcting for
multiple comparisons, targets of miR-10b-5p, miR-196a, miR-
196b and miR-615-3p shared significant overlap in 33 biological
functions; the top three functional categories were ‘‘Cell Death and
Survival,’’ (Benjamini-Hochberg adjusted p-value, range = 3.5e-07–
1.5e-04), ‘‘Nervous System Development and Function’’ (range = 1.5e-07–
1.5e-03) and ‘‘Cellular Assembly and Organization’’ (range = 2.5e-05–
1.7e-03). Twelve pathways were shared among all four sets of
miRNA targets, including ‘‘Huntington’s Disease Pathway’’ (ran-
ge = 7.6e-04–8.1e-03), (Gene set =AKT1, BAX, CAPSN1, CLTC,
CREB1, EGFR, HDAC9, JUN, MAPK8).
mRNA targets of differentially expressed miRNAs are
differentially expressed
Total mRNA-sequencing was performed in the same brain
samples as miRNA-sequencing to examine whether gene expression
was affected by miRNA up-regulation. Of the 169 unique gene
targets for the five differentially expressed miRNAs, 167 were
detected using mRNA-sequencing. 22 mRNA targets were signifi-
cantly differentially expressed between the HD and control prefrontal
cortex samples (False Discovery Rate (FDR) adjusted q-value=0.05
after adjusting for 167 comparisons). Only one gene (keratin 5, KRT5)
was down-regulated in HD (Table 4), and four of these target genes
were located in the Hox clusters (HOXD4, HOXA10, HOXB7 and
HOXD10).
miR-10b-5p, miR-196a-5p, miR-196b-5p and miR-615-3p
expression is related to Hox cluster gene expression
Four of the five up-regulated miRNAs are located intergenic to
Hox gene clusters (Figure 3). Because of gene duplication, miR-
196a is derived from both the HOXB and HOXC clusters; miR-
10b is located in the HOXD cluster and miR-615 is found in the
HOXC cluster [31,32]. A total of 55 genes (40 protein-coding
genes, eleven antisense transcripts, three functional lncRNAs and
one pseudogene) are located in the four Hox clusters [33,34]. To
evaluate evidence for a general regional up-regulation of Hox
cluster genes, an expression analysis of the mRNA-sequence data
was performed for all annotated genes within the Hox loci
(Table 5). Fifteen out of 55 genes within the Hox loci were
differentially expressed in HD. Fourteen Hox genes were
significantly up-regulated (FDR-adjust q-value,0.05, mean fold-
change= 6.73, range 3.02 to 16.12) and a single Hox gene was
down-regulated (HOXD1, FDR-adjust q-value = 3.92e-02, fold
change=22.45). The majority of differentially expressed Hox
genes (13 out of 15) were essentially unexpressed in controls.
The genes adjacent to the four differentially expressed miRNAs
were highly expressed. Two genes immediately adjacent to miR-
10b-5p were significantly up-regulated in HD (HOXD4, FDR-
adjusted q= 3.22e-03; HOXD8, FDR-adjusted q= 2.07e-03),
(Figure 4). HOXB9 (FDR-adjusted q-value = 3.22e-03) immedi-
ately downstream of miR-196a-1 and HOXC10 (FDR-adjusted q-
value = 4.14e-02) immediately upstream of miR-196a-2 were also
up-regulated. Furthermore, all three Hox genes located upstream
of miR-196b were significantly up-regulated in HD (HOXA10,
FDR-adjusted q-value = 1.11e-02; HOXA11, FDR-adjusted q-
value = 2.07e-03; HOXA13, FDR-adjusted q-value = 2.24e-02).
HOXC6 (FDR-adjusted q-value = 1.27e-02) immediately upstream
of miR-615 was also up-regulated.
Discussion
Up-regulation of expression for five miRNAs in HD brain
We report a next-generation sequencing study of small RNAs,
identifying 1,417 mature miRNA species in the prefrontal cortex
(Brodmann Area 9) of twelve HD and nine control brains. Five of
these, miR-10b-5p, miR-196a-5p, miR-196b-5p, miR-615-3p and
miR-1247-5p, were up-regulated in HD at genome-wide signifi-
cance (FDR q-value,0.05), and three of these five, miR-196a-5p,
miR-196b-5p and miR-615-3p, were expressed at near zero levels
in the control brains. Up-regulation of miR-10b-5p was validated
in the miRNA-sequencing samples and confirmed in an indepen-
dent replication sample set. Several studies implicating a role for
miRNAs in HD have been performed, although, to our knowledge
this is the first genome-wide quantification of miRNA expression
comparing individual human HD and control brain samples.
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Packer et al. [11], studying an array of 365 mature miRNAs,
had previously reported miR-196a-5p to be significantly increased
by nearly six-fold in Brodmann Area 4 of HD grade 1 brains.
Recently, a study by Cheng et al. [13] found increased miR-196a
expression suppressed mutant HTT expression in both HD
neuronal cell models and HD transgenic mouse models. These
Table 4. 22 differential expressed targets of miR-10b-5p, miR-196a, miR-196b, miR-1247 and miR-615-3p.
Target
gene miRNA Location
Mean Control
Expression (n=9)
Mean HD
Expression (n =12) Fold Change p-value q-value*
SERPINE1 miR-10b-5p 7q22.1 22.91 140.82 6.15 3.03E-11 5.06E-09
CDKN1A miR-196a 6p21.2 336.73 841.75 2.5 1.58E-04 1.22E-02
HOXD4 miR-10b-5p 2q31.1 1.74 18.33 10.51 2.38E-04 1.22E-02
ANXA3 miR-10b-5p 4q21.21 259.93 553.71 2.13 2.92E-04 1.22E-02
TWIST1 miR-10b-5p 7p21.2 43.43 105.16 2.42 5.63E-04 1.72E-02
CD33 miR-196a, miR-196b 19q13.3 16.58 46.63 2.81 6.75E-04 1.72E-02
DIO3 miR-1247 14q32 10.89 41.93 3.85 7.29E-04 1.72E-02
MMP2 miR-10b-5p 16q13-q21 58.67 137.83 2.35 8.26E-04 1.72E-02
MMP9 miR-10b-5p 20q11.2-q13.1 5.32 17.33 3.26 9.33E-04 1.73E-02
HOXA10 miR-10b-5p, miR-196a, miR-196b 7p15.2 1.06 17.06 16.12 1.21E-03 1.73E-02
RHOD miR-10b-5p 11q14.3 12.71 37.96 2.99 1.23E-03 1.73E-02
COL1A1 miR-196a 17q21.33 30.19 220.28 7.3 1.31E-03 1.73E-02
HLA-E miR-10b-5p 6p21.3 3703.47 7769.76 2.1 1.34E-03 1.73E-02
PPARA miR-10b-5p 22q13.31 444.7 865.02 1.95 1.53E-03 1.73E-02
PAX6 miR-196a 11p13 693.52 1337.23 1.93 1.62E-03 1.73E-02
EGFR miR-10b-5p 7p12 784.95 1762.88 2.25 1.66E-03 1.73E-02
HOXB7 miR-196a 17q21.3 1.63 6.99 4.28 2.83E-03 2.78E-02
PLAUR miR-10b-5p 19q13 56.15 119.67 2.13 3.65E-03 3.38E-02
HOXD10 miR-10b-5p 2q31.1 1.25 9.33 7.45 4.73E-03 3.96E-02
RUNX1 miR-10b-5p 21q22.3 87.69 224.88 2.56 4.74E-03 3.96E-02
SOX2 miR-10b-5p 3q26.3-q27 1963.76 3492.72 1.78 5.32E-03 4.23E-02
KRT5 miR-196a 12q13.13 113.74 51.99 22.19 6.00E-03 4.55E-02
* FDR-adjusted q-value for 167 targets of the five miRNAs.
doi:10.1371/journal.pgen.1004188.t004
Table 5. Differential expression of Hox cluster genes in HD.
Gene
Mean Control Expression
(n =9) Mean HD Expression (n =12) Fold Change p-value q-value*
HOXA11 1.06 8.20 7.75 3.96e-05 2.07e-03
HOXA5 1.06 7.63 7.21 1.03e-04 2.07e-03
HOXD8 1.15 7.84 6.80 1.13e-04 2.07e-03
HOXD4 1.74 18.33 10.51 2.38e-04 3.22e-03
HOXB9 1.06 9.20 8.69 2.93e-04 3.22e-03
HOXA10 1.06 17.06 16.12 1.21e-03 1.11e-02
HOXC6 1.15 6.16 5.34 1.62e-03 1.27e-02
HOXA11-AS 1.25 7.39 5.90 2.49e-03 1.71e-02
HOXB7 1.63 6.99 4.28 2.83e-03 1.73e-02
HOXA13 1.45 8.74 6.03 4.07e-03 2.24e-02
HOXD10 1.25 9.33 7.45 4.73e-03 2.36e-02
HOXD1 55.91 22.80 22.45 8.55e-03 3.92e-02
HOXC10 1.36 8.04 5.90 1.06e-02 4.14e-02
HOXC4 3.57 10.77 3.02 1.12e-02 4.14e-02
HOTAIRM1 3.52 12.52 3.56 1.13e-02 4.14e-02
* FDR-adjusted q-value for the 55 genes in the four Hox clusters.
doi:10.1371/journal.pgen.1004188.t005
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findings suggest increased expression of miR-196a may be an
adaptive response, promoting neuronal survival and may have
therapeutic implications for HD. Miyazaki et al. [35] studied miR-
196a in spinal and bulbar muscular atrophy (SBMA), a
neurodegenerative disease caused by a similar polyglutamine
repeat expansion in the androgen receptor (AR) gene. They found
increased miR-196a expression via adeno-associated virus vector-
mediated delivery reduced AR mRNA levels leading to improved
neurological function in transgenic SBMA mouse models.
Together, these findings suggest a neuroprotective role for miR-
196a and its targets and possible therapeutic implications across
multiple polyglutamine-expansion neurodegenerative diseases.
miR-196a-5p and miR-10b-5p were among the 56 miRNAs found
to be elevated in response to mutant HTT over-expression in
undifferentiated NT2 cells [36]. According to the miRNA search
program ‘‘PubmiR,’’ [37] miR-196b-5p, miR-1247-5p and miR-
615-3p have not been previously reported in HD miRNA studies.
A number of past studies have examined miRNA levels in HD,
HD transgenic mice or cellular models; however, we did not
replicate the results obtained in these studies. Gaughwin et al. [36]
reported miR-34b elevated in plasma samples in HD, but we
found neither miR-34b-3p nor miR-34b-5p to be altered in HD
brain at genome-wide levels. We were not able to confirm any of
the miRNAs reported in past microarray studies that examined
targeted subsets of miRNAs, including the nine miRNAs reported
as down-regulated in two mouse models of HD (YAC128 and R6/
2) by Lee et al. [14] using a 567 miRNA microarray or the 38
miRNAs with altered expression in HD transgenic mice in a 382
miRNA microarray [15]. Johnson et al. [10–12] reported miR-29a
and miR-330 to be significantly up-regulated in HD samples,
neither of which was found to be altered in this study [10]. In a
RT-qPCR study comparing 90 miRNAs in mouse Hdh (Q111/
Q111) striatal cells to control mice [12,38], none of the 27
reported differentially expressed miRNAs was different at genome-
wide levels in our study. The most commonly reported altered
miRNA in HD studies, miR-132, has been reported as both down-
regulated [10,14,39] and up-regulated [11], but was not differen-
tially expressed in our study.
While some of the lack of concordance may be a consequence of
the differences between human and animal models of HD, it is also
likely that some of the differences are a consequence of the
different technologies employed by these studies. Microarrays may
have different levels of detection for some miRNAs from that seen
by miRNA sequencing. Finally, nearly all of the studies employ
microarray methods. Microarrays that study only 365 (e.g. Packer
et al. [11],) to 567 miRNAs (e.g. Lee et al. [14]) are not performing
as many contrasts and thus do not adjust for as many contrasts as
our genome wide analysis (e.g. 1,417 miRNAs detected) demands.
miR-10b-5p, miR-196a-5p, miR-196b-5p and miR-615-3p
implicate Hox cluster genes
Four (miR-10b-5p, miR-196a-5p, miR-196b-5p and miR-615-
3p) of the five differentially expressed miRNAs are related to Hox
cluster genes as follows: (1) these four are located in intergenic
regions of the Hox clusters, (2) eleven Hox genes are validated
targets of these four miRNAs, (3) Hox genes adjoining differen-
tially expressed miRNAs are differentially expressed and (4)
multiple Hox cluster genes are differentially expressed in HD
versus control brains (Table 4).
Figure 4. Differentially expressed miRNAs in HD are located in Hox genes clusters. Schematic representation of Hox clusters. Hox genes
are represented as numbered boxes (labeled 1–13), miRNA are represented by triangles and other genes in the regions (functional lncRNA, PRAC) are
represented by rectangles. Antisense transcripts and pseudogenes are not pictured. Nineteen genes within Hox cluster regions were found
significantly differentially expressed in HD prefrontal cortex using mRNA-sequencing (FDR-adjusted p-value,0.05). Four miRNAs, one lncRNA, and
fourteen Hox genes were significantly up-regulated in HD (indicated by red), many of which are adjacent to differentially expressed miRNAs. A single
Hox gene (HOXD1) was down-regulated in HD (indicated by blue). (HD=Huntington’s disease).
doi:10.1371/journal.pgen.1004188.g004
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Of the eleven Hox gene targets, eight did not differ in their
expression across condition. A single target, HOXD1 was seen to
be down-regulated in HD (FC=22.45). HOXD1 is a reported
target of four of the five miRNAs [40] which may explain its
repression in HD.
Three Hox gene targets were up-regulated in HD (HOXB7,
HOXD4 HOXD10). It is possible these up-regulated Hox genes
share similar regulatory mechanisms, as the increased miRNA
expression does not produce the expected miRNA-mediated gene
silencing and suppress the observed up-regulation of the miRNA
target genes. Coevolution of Hox genes and Hox-related miRNAs
may further suggest that they share regulatory elements or
mechanisms [41]. Furthermore, Hox genes and related miRNAs
have been observed to have similar patterns of transcriptional
activation and both are activated by retinoic acid [42–46].
Although miR-10b-5p has been validated as targeting HOXD4,
they may exhibit patterns of co-expression. Specifically, Phua et al.
[45] report miR-10b and HOXD4 are temporally co-expressed
during neurodifferentiation. Here, we see a similar up-regulation
and co-expression pattern in HD, where miR-10b and HOXD4 are
both highly expressed.
Hox genes are a family of transcription factors that contribute to
major morphological changes during embryonic development and
are required for anterior-posterior body axis in bilaterally develop-
ing species [47]. They are highly involved in most aspects of early
development, and are prominently expressed in the developing
brain [48]. Hox-related miRNAs may also follow similar spatio-
temporal patterns of expression during embryogenesis [49].
Hox genes are regulated by retinoic acid but also other factors,
including basic fibroblast growth factor [50], steroid hormones
[51,52] and polycomb repressive complex group [53]. Polycomb
group (PcG) proteins assemble into large silencing complexes and
control histone-modifying activity. Hox genes are repressed by PcG
complexes, specifically Polycomb Repressive Complex 2 (PRC2),
which trimethylates histone H3 at lysine 27 (H3K27me3) [53].
Seong et al [54] observed knockout huntingtin mouse embryos
lacked repression of HOXB1, HOXB2, and HOXB9 and showed
diminished global H3K27me3, while a knock-in expanded repeat
mouse exhibited increased H3K27me3 signal, suggesting mutant
huntingtin may alter proper PRC2 activity. These findings raise
the possibility that the increased expression of miRNAs and Hox
genes reported here are related to enhanced H3K27me3 or
impaired PcG repression. However, the role of Hox in the adult,
HD brain is still unclear. Increased transcriptional activity of Hox
may be compensatory, helping to preserve or re-establish cell
polarity, or an indirect result of impaired epigenetic regulation.
miR-10b-5p response in HD may be protective
To functionally validate our miRNA-sequencing findings, we
chose to assess miR-10b-5p. We believed this miRNA to be the
most biologically active of the differentially expressed miRNAs.
miR-10b-5p had the highest basal expression levels and the highest
fold change between conditions. Additionally, miR-10b-5p levels
were not increased in PD, a comparable protein aggregate,
neurodegenerative disease, nor in PD samples with pathology in
the prefrontal cortex equivalent to HD.
To determine whether miR-10b-5p had a protective or
deleterious effect on neuron viability, we ectopically expressed
miR-10b-5p in terminally differentiated PC12 Q73 cells. Since the
levels the five differentially expressed miRNA were up-regulated,
we felt overexpression of miR-10b-5p best represented the
phenotype observed in HD brain.
We reported increased miR-10b-5p expression enhanced the
survival of PC12 Q73 cells. Furthermore, we found that increased
miR-10b-5p expression enhanced survival in the presence of
apoptosis-inducing compound, MG 132. In this experiment,
survival in cells with increased miR-10b-5p expression was
comparable to that of unchallenged cells and significantly greater
than untreated cells exposed to toxin. These finding provide
support for the hypothesis that increased miR-10b-5p may be a
neuroprotective response to the expanded polyglutamine repeat
seen in HD and speaks to the role of this microRNA in the
pathology of HD.
miR-10b-5p, miR-196a-5p, miR-196b-5p and miR-615-3p
have overlapping biological functions
Using pathway analysis, we showed that miR-10b-5p, miR-196a-
5p, miR-196b-5p and miR-615-3p targeted genes are predicted to
be involved in apoptosis as well as nervous system development and
function. In neuroblastoma SH-SY5Y cell lines, miR-10a, miR-10b
and miR-615-5p expression levels significantly increased during all-
trans-retinoic-acid (ATRA) treatment, indicating miR-10a/b and
miR-615-5p may have a role in neurodifferentiation [44]. SH-
SY5Y cells treated with antisense miR-10a or miR-10b had
impaired neurite outgrowth and morphology but did not show
changes in overall cell proliferation [44]. miR-10a and miR-10b
were highly expressed in SK-N-BE, LAN5 and SH-SY5Y cell lines
during ATRA treatment and ectopic expression of miR-10ab
mirrored the phenotype of the ATRA treatment [42]. Taken
together, these studies implicate these miRNAs in neuron differen-
tiation, migration, and outgrowth.
In our past studies [16], we found increased neurite outgrowth
in HD prefrontal cortex. Relative to controls, HD pyramidal
neurons had a significantly increased number of primary dendritic
segments, increased total dendritic length, and more dendritic
branches than control neurons. Here, we report four miRNAs that
have been observed in cell models to present a similar phenotype.
It is possible that increased expression of these miRNAs and
related targets represent an adaptive response of neurons stressed
by a toxic expanded polyglutamine protein fragment.
miR-10b-5p, miR-196a-5p, miR-196b-5p and miR-615-5p
are related to HD pathogenesis
Four of the five up-regulated miRNAs showed association to
clinical features of HD (CAG repeat size, age of motor onset and
age at death for miR-10b-5p; CAG repeat size and age at onset for
miR-196a-5p, age at onset for miR-196b-5p and age at death for
miR-615-3p). Due to the near zero level of expression in controls,
it was not possible to assess the relationship of miR-196a-5p, mir-
196b-5p and miR-615-3p to age at death, but miR-10b-5p was not
correlated with age at death in controls. Thus, the increased
expression of these miRNAs did not appear to be related to
normal aging, but rather a component of gene regulation and
transcription in the context of neurodegeneration. A growing body
of literature points to the presence of toxic effects of the HD gene
substantially before the onset of symptoms, perhaps from the time
of conception [55–57].
Because age at death represents the lifetime exposure of the
individual to the effects of the HD gene, we hypothesize that the
association of miR-10b-5p and miR-615-3p with age at death may
represent the lifetime exposure to the effects of the HD mutation.
If the relationship of altered miRNA expression to age at death
supports the view that the HD gene may have a life-long effect
among expanded CAG-repeat carriers, this raises the possibility
that the HD mutation may influence neuronal development in the
developing brain through the action of one or more of these
miRNAs and Hox cluster genes.
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Target genes of over-expressed miRNAs show increased
expression in HD
We report five miRNAs as being highly up-regulated in HD and
though our expectation was to see the mRNA targets of these
miRNAs as decreased, we observe increased expression of many of
their shared mRNA targets. We believe these effects are not
attributable to differences in cell populations studied, since flow
cytometric analysis measuring neuron abundance found no
significant difference across condition. Rather, we hypothesize
positive miRNA-mRNA target relationships are a result of HD-
specific alterations in mRNA processing.
Translation is a highly dynamic process. Cytoplasmic mRNA
actively engaged in translation can cycle to a non-translated state
and accumulate in stress granules or processing bodies (P-bodies).
During cellular stress, mRNA can be sequestered to P-bodies or
stress granules, to stall translation through translational repression
machinery or miRNA silencing, until stress conditions have been
resolved [7,58–60]. P-bodies may also serve an important role in
RNA transport. Because neurons are highly polarized, cytoplasmic
transport of mRNA is essential for localized translation to discrete
regions of the cell. During transport, it is believed that mRNAs are
silenced by miRNA, upon rapid exchange at the synapse [60–62].
In HD cortical neurons, excitotoxicity, oxidative damage,
aberrant gene expression and energetic defects lead to stress
conditions and in response, cells may sequester mRNA to P-bodies
and stress granules. Among the 55 Hox locus genes studied, only
one of the fifteen significantly differentially expressed genes is
down regulated (Table 4). Thus, the increased levels of most of
the validated gene targets of these four miRNAs may be
reactionary, as they are sequestered to P-bodies for storage as
part of a protective process to enhance cell viability [7].
To the best of our knowledge, no study has addressed the role of
P-bodies or stress granules in HD. However, it was observed in live
cortical neurons that wildtype huntingtin co-localized in P-bodies,
specifically in neuronal RNA granules, along with Argonaute 2,
the endonuclease required for RNA-mediated gene silencing by
the RNA-induced silencing complex (RISC) [63,64]. Therefore, it
is reasonable to suggest mutant huntingtin may impair miRNA-
mediated mRNA degradation and/or localized translation of
specific mRNAs.
There is evidence that miRNA-mRNA regulatory mechanisms
may be altered in other neurodegenerative diseases as well. In a
joint examination of miRNA-mRNA expression in Alzheimer’s
disease (AD) and control prefrontal cortex, an overwhelming
number of miRNA to mRNA targets were found to be positive
correlated. Genomic variants in TDP-43 and FUS, genes that
encode stress granule proteins, were found to cause familial
Amyotrophic lateral sclerosis [65,66] and several other stress
granule proteins (TIA-1, G3BP) may also be pathogenic [67].
miRNAs as potential biomarkers in HD
These studies suggest potential relationships of these miRNAs to
CAG repeat expansion, age at onset or age at death. If these
findings hold up on further examination, these miRNAs may hold
potential to provide insight into important biological and disease
expression for HD. miRNA are extremely stable. The half-life of
the majority of miRNAs has been predicted to be on average five
days and plasma miRNAs have been found to be stable after being
subjected to high heat, extreme pH, long-time storage at room
temperature, or multiple freeze-thaw cycles [68–70]. If these
miRNAs cross the blood-brain barrier and can be detected at
reasonable levels in serum/plasma from mutant HD gene carriers,
they may serve as biomarkers of disease expression.
Materials and Methods
Sample information
Frozen brain tissue from prefrontal cortex Brodmann Area 9
(BA9) was obtained from the Harvard Brain and Tissue Resource
Center (HBTRC) McLean Hospital, Belmont MA. Twelve
Huntington’s disease (HD) samples and eleven neurologically-
normal control samples were selected for the study (Table 1). The
HD subjects had no evidence of Alzheimer or Parkinson disease
(PD) comorbidity based on neuropathology reports. For micro-
scopic examination, 16 tissue blocks were systematically taken and
histologically assessed as previously described [3]. All samples were
male. HD samples and controls were not different for postmortem
interval (PMI) (t = 1.07, p = 0.30), RNA integrity number (RIN)
(t = 0.83, p = 0.41) or death age (t = 0.40, p = 0.69). CAG repeat
size was known for all HD samples and onset age and disease
duration was unknown for a single sample (Table 1). Eight
additional HD, nine control and fourteen PD cases were studied as
part of validation and replication studies, and were obtained from
the HBTRC and the Sun Health Research Institute Sun City,
Arizona (Tables S2, S3 and S5).
RNA extraction
Total RNA, for all samples studied, was isolated using QIAzol
Lysis Reagent and purified using miRNeasy MinElute Cleanup
columns (Qiagen Sciences Inc, Germantown, MD). RNA quality
for sequencing was assessed using either Agilent’s BioAnalyzer
2100 system and RNA 6000 Nano Kits to find RNA Integrity
Number (RIN) or Agilent 2200 TapeStation and DNA Screen-
Tape assay RNA Quality Number (RQN; Agilent, Foster City,
CA). Both methods calculate the area under the peak for 18S and
28S RNA as a ratio of total RNA as well as the relative height of
the 18S and 28S peaks to determine RNA quality [71]. The RIN/
RQN values were similar for the twelve HD and eleven control
specimens studied for miRNA and mRNA (t = 0.95, p = 0.36).
Illumina miRNA sequencing (miRNA-seq)
For each brain sample, 1 ug of RNA was used to construct
sequencing libraries using Illumina’s TruSeq Small RNA Sample
Prep Kit, according to the manufacturer’s protocol (Illumina, San
Diego, CA). In brief, small RNA molecules were adapter-ligated,
reverse transcribed, PCR amplified and gel purified to generate
the library. Multiplexed samples were equimolarly pooled into sets
of eight samples per flowcell lane and sequenced using 1650 bp
single-end reads on Illumina’s HiSeq 2000 system at Tufts
University sequencing core facility (http://tucf-genomics.tufts.
edu/). Demultiplexing and FASTQ file generation (raw sequence
read plus quality information in Phred format) were done using
Illumina’s Consensus Assessment of Sequence and Variation
(CASAVA) pipeline.
Primary processing of Illumina miRNA-seq reads
Sequence read quality was evaluated using the FASTQ quality
filter module from the FASTX-toolkit version 0.0.13 (http://
hannonlab.cshl.edu/fastx_toolkit/), and only those reads with at
least 80% of the base calls above Q20 (Phred score) were retained.
The 39 adapter sequence (59-TGGAATTCTCGGGTGC-
CAAGG-39) was removed from all reads using the FASTA/Q
clipper module from the FASTX-toolkit. A minimum length
threshold of 15 nucleotides was set for clipped reads because
miRNAs of this length will contain the seed sequence. To avoid
redundancy amongst identical read species, the reads were
collapsed using the FASTA/Q collapser module from FASTX-
toolkit to generate a FASTA file of only the unique read species.
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Alignment and mapping of miRNA-seq reads
Quality-filtered, 39 adapter-clipped reads were aligned to the
UCSC human reference genome (build hg19) using Bowtie version
0.12.3 [72]. Alignment parameters were set to allow for no
mismatch alignments and no limits on multiple mapping instances.
Multiple-mapped identical sequences were summed for a single
count for that annotated mature miRNA. The default settings
were used for all other alignment options.
The miRNA aligned data are available on ArrayExpress
(http://www.ebi.ac.uk/arrayexpress/), accession number E-
MTAB-2206.
miRNA abundance estimation
Aligned reads that overlapped with the human miRNA
annotation version 19 from miRBase (http://www.mirbase.org/
ftp.shtml) were identified using default BEDTools’ IntersectBed
functionality [73]. To select for mature miRNA reads, sequences
more than 27 bases in length were removed. Only those reads for
which the aligned 59 start-nucleotide matched exactly to the 59
start-nucleotide of the annotated miRNA were retained for the
analysis. After filtering, collapsed read counts were summed per
annotated mature miRNA (Table S6).
miRNA differential expression
The R (http://www.R-project.org) package DESeq version
1.10.1 [28] was used to perform the differential expression analysis
between HD and control samples using the read counts generated
for each sample as described above. miRNAs with zero read
counts across all case and control samples were removed from
analysis. To accommodate the analysis of miRNAs with read
counts of zero for some samples, a pseudo-count of one was added
to all raw counts for every miRNA across all the samples, prior to
performing DESeq’s estimateSizeFactors and estimateDispersions
functions with default options. DESeq assumes that count data
follow a negative binominal distribution and factors in technical
and biological variance when testing for differential gene
expression between groups. DESeq’s function, estimateSizeFac-
tors, was used to obtain normalization factors for each sample and
to normalize miRNA read counts.
The normalized counts were evaluated by principal component
analysis (PCA) with the FactoMineR R package for all HD and
control samples. The samples identified to be three or more
standard deviations away from the mean on the first or second
principal component were considered outliers and were removed
from analysis. The first two principal components were used
because they each explained more than 10% of the variance, while
the remaining principal components explained less than 10% of
the variance. Two control samples (C-35 and C-37) were identified
as outliers based on PCA analysis.
miRNA differential expression analysis was performed with
DESeq’s nbinomTest function for the remaining nine control and
twelve HD samples. All analyses were performed on DESeq
normalized counts.
miRNA quantitative PCR
miRNA were assayed using Exiqon’s miRCURY LNA Univer-
sal RT miRNA PCR following the manufacturer’s protocol
(Exiqon Inc, Denmark). In brief, reactions were incubated for
60 min at 42uC followed by heat-inactivation of reverse
transcription for 5 min at 95uC and stored at 4uC. After cDNA
synthesis, samples were diluted to 0.2 ng/ul in water. Brain
samples were assayed using Exiqon ExiLENT SYBR Green
master mix and LNA primer sets containing UniRT and miR-
10b-5p, miR-196a-5p, miR-196b-5p, miR-615-3p or miR-1247.
Reference primer hsa-SNORD48 PCR/UniRT was used for
brain samples; U6 snRNA for cell lines. Samples were run in
triplicate for each primer set in 384-well format (5 ul PCR Master
mix, 1 ul PCR primer mix, 4 ul 0.2 ng cDNA). Reactions were
cycled using Applied Biosystems 7900HT Fast Real-Time PCR
System using manufacturer’s instructions (Life Technologies,
Carlsbad, CA). For analysis, threshold cycle (CT) was generated
by ABi SDS v2.4 software. CT values for triplicate wells were
normalized by average RNU48 value for brain or U6 for cells.
miRNA fold change was calculated using the 2-DDCTmethod [74].
Neuron abundance quantification
0.5–1.0 g of tissue in 5 ml of lysis buffer was homogenized using
a dounce tissue grinder. Lysates were transferred to ultracentri-
fugation tubes, loaded on top of sucrose solution and centrifuged
at 24,400 RPM for 2.5 hr at 4uC (Beckman Coulter, Pasadena,
CA; L8-70 M with SW80 rotor). Nuclei pellets were resuspended
in 500 ul PBS and incubated at 4uC in a staining solution
containing 0.72% normal goat serum, 0.036% BSA, 1:1200 anti-
NeuN (Millipore, Germany), 1:1400 Alexa488 goat anti-mouse
secondary antibody (Life Technologies, Carlsbad, CA), for
45 min. Flow cytometry was performed at the Boston University
Medical School Flow Cytometry Core Lab on a FACSVantage SE
flow cytometer.
Illumina messenger RNA sequencing (mRNA-seq)
For each brain sample, 1 ug of RNA was used to construct
sequencing libraries using Illumina’s TruSeq RNA Sample Prep
Kit according to the manufacturer’s protocol. In brief, mRNA
molecules were polyA selected, chemically fragmented, randomly
primed with hexamers, synthesized into cDNA, 39 end-repaired
and adenylated, sequencing adapter ligated and PCR amplified.
Each adapter-ligated library contained one of twelve TruSeq
molecular barcodes. Multiplexed samples were equimolarly pooled
into sets of three samples per flowcell lane and sequenced using
26100 bp paired-end reads on Illumina’s HiSeq 2000 system at
Tufts University sequencing core facility (http://tucf-genomics.
tufts.edu/). Demultiplexing and FASTQ file generation were
accomplished using Illumina’s CASAVA pipeline.
Primary processing of Illumina mRNA-seq reads
Forward and reverse sequencing reads were independently
quality-filtered using the FASTQ quality filter module from the
FASTX-toolkit version 0.0.13 (http://hannonlab.cshl.edu/
fastx_toolkit/) with the same criteria as that applied for the
processing of the miRNA-seq reads. Reads failing the quality
threshold, as well as their corresponding mate reads, were
removed.
Alignment and mapping of mRNA-seq reads
Quality-filtered paired-end reads were aligned to the UCSC
human reference genome (build hg19) using TopHat version 2.0.4
[75,76]. This version of TopHat incorporates the Bowtie version
2.0.0.7 algorithm to perform the alignment [72] as well as
SAMtools version 0.1.18.0 for alignment file formatting [77]. For
efficient read mapping, TopHat requires the designation of the
mean and standard deviation of the distance between paired-end
reads, the read inner-distance. To estimate the appropriate read
inner-distance, we aligned a subset of 5 million reads from four
HD and four control samples to the Ensembl human reference
transcriptome (release 66) using Bowtie version 2.0.0.7. Using the
CollectInsertSizeMetrics function from picardTools version 1.76
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(http://sourceforge.net/projects/picard/files/picard-tools/), we
estimated the average mean inner-distance per condition and
subsequently applied these values for the TopHat alignment; 22
for HD samples 25 for controls respectively, (the current TopHat
default setting is 20), (Table S7). To account for read variability,
the standard deviation for inner-distance was set to 100. The
number of allowed splice mismatches was set to 1. Default settings
were used for all other alignment options.
mRNA gene abundance estimation
Gene expression quantification was performed using htseq-
count version 0.5.3p9 (http://www-huber.embl.de/users/anders/
HTSeq) and the GENCODE version 14 annotation gtf file as
reference (http://www.gencodegenes.org/releases). Intersection
non-empty mode and unstranded library type were specified as
parameters for htseq-count. Default settings were used for all other
options (Table S8).
mRNA differential expression analysis
The mRNA differential expression analysis between HD and
control samples was performed using DESeq version 1.10.1 [28]; the
workflow was the same as described for the miRNA differential
expression analysis. No outliers were found based on the PCA of the
DESeq-normalized count data. The nbinomTest function was run
for eleven control samples and twelve HD samples to assess
differentially expressed genes. Multiple comparison adjustment for
multiple testing with the Benjamini-Hochberg correction was used to
control for false discovery rate. For Hox gene differential expression
analysis, 55 comparisons were used. Genes located within HOX-
gene containing regions were queried through the Ensembl database
(release 72), interfacing through the R package BiomaRt [78,79].
Genes that were between HOXA1-HOXA13, HOXB1-HOXB13,
HOXC4-HOXC13 andHOXD1-HOXD13 start sites were regarded as
‘‘Hox genes.’’ For miRNA target differential expression, 154
comparisons were used for Benjamini-Hochberg correction.
miRNA-mRNA target analysis
Information on experimentally validated miRNA targets of
miR-10b-5p, miR-196a-5p and miR-615-3p were extracted from
the miRWalk ‘‘Validated Targets’’ module [30]. Strand specificity
was preserved. Targets for miR-196a-1 and miR-196a-2 were
merged for analysis. IPA Core Analysis (analysis.ingenuity.com)
was run as nervous system and CNS cell line specific across all
species, using target gene lists imported from miRWalk output.
‘‘Bio Functions’’ and ‘‘Canonical Pathway’’ analyses were used.
Right-tailed Fisher’s Exact Tests were run through IPA software
and p-values with FDR-adjusted q-values (p,0.05) were consid-
ered significant. Biological functions across the 3 significant
miRNA were compared using the IPA Core Comparison Analysis
tool. Benjamini-Hochberg Multiple Testing Correction p-values
(p,0.05) were considered significant.
Linear modeling of miRNA relationship to clinical
covariates
To account for the non-normality in the miRNA data, negative
binominal general linear regressions were performed using Proc
genmod in SAS. DESeq normalized counts were rounded to the
nearest integer before running the model. To test the normality of
gene expression data, Shapiro-Wilk tests were performed. Differ-
entially expressed miRNA data trended as non-normally distrib-
uted in HD (miR-10b-5p, p = 0.04; miR-196a-5p, p = 0.05; miR-
615-3p, p = 0.06), but not in controls (miR-10b-5p, p= 0.71; miR-
196a-5p and miR-615-3p were essential zero).
Generation of transgenic cell lines
PC12 (rat adrenal gland phaeochromocytoma) cells were grown
at 37uC and 5% CO2 in Dulbecco’s modified Eagle’s medium
(DMEM; Life Technologies, Carlsbad, CA) with 20% fetal bovine
serum (FBS; Atlanta Biologicals, Flowery Branch, GA), 100 units/
ml penicillin and 100 units/ml streptomycin (Life Technologies,
Carlsbad, CA). pcDNA3.1mycC expressing human huntingtin
fragment (1–90) containing 73 polyglutamine repeats (Coriell
Institute; CHDI-90000034) was used for stable transfection. Cells
were seeded to 70% confluency and grown overnight. 15 ml of
Attractene Transfection Reagent (Qiagen, Gaithersburg, MD) was
added to 4 mg plasmid DNA diluted in 300 ml Opti-MEM (Life
Technologies, Carlsbad, CA). Cells were grown in complete media
and selected for four weeks using 500 mg/ml G418 (Life
Technologies, Carlsbad, CA). To create monoclonal cultures,
single colonies were isolated using dilution cloning, picked with
filter paper, grown in a 6-well plate and screened for transgenic
expression by Western blot analysis using mouse Anti- c-Myc
(Novex, R950-25, Life Technologies, Carlsbad, CA).
Cell differentiation and miRNA overexpression
96-well culture plates were seeded with 10,000 cells per well.
For differentiation, culture medium was replaced with medium
composed of DMEM with 0.5% FBS, 100 mg/ml G418, 100
units/ml penicillin and 100 units/ml streptomycin and 100 ng/ml
nerve growth factor (R&D Systems, Minneapolis, MN). After
48 hr, miRNA was transfected into HD cells using 0.25 ul
Lipofectamine 2000 (Life Technologies, Carlsbad, CA) and
6.25 pmol miR-10b-5p or miRIDIAN microRNA Mimic Nega-
tive Control #1 (cel-miR-67-3p, Thermo Scientific, Waltham,
MA) per well, following manufacturer’s protocol. miR-10b-5p
overexpression was verified using qPCR.
Cell viability assays
For MTT assays, 1 uM MG 132 (Tocris Bioscience, United
Kingdom) was added to select wells containing 10,000 cells per
well at 72 hr post-differentiation. Cell viability was assessed at
96 hr post-differentiation. Following manufacturer’s protocol,
CellTiter 96 Non-Radioactive Cell Proliferation Assay kit
(Promega; Madison, WI) was used to determine cell number.
Cells were incubated for 1.5 hr at 37uC and 5% CO2 with MTT
dye solution. Undifferentiated HD cells were serially diluted across
a 96-well plate to create a standard curve for cell number
calculation. Absorbance was measured using Bio-Tek Synergy H1
spectrophotometer at 540 nm for miR-10b-5p transfected wells,
with MG 132 (n= 44) and without MG 132 (n= 35) and cel-miR-
67-3p transfected wells with MG 132 (n = 40) and without MG
132 (n= 40). One-way ANOVA way used for statistical analysis.
For cell viability staining, miR-10b-5p and negative control
mimic were transfected after 48 hours of differentiation in 12-well
culture plate with 4 replicates each, 250,000 cells per well.
Molecular Probes Neurite Outgrowth Staining Kit (Life Technol-
ogies, Carlsbad, CA) was used according to manufacturer’s
protocol. Using Bio-Tek Synergy H1 microplate reader, fluores-
cent area scans were taken at 530 nm excitation/590 nm emission
with a 565 matrix per well.
Supporting Information
Figure S1 Neuron counts from prefrontal cortical tissue
homogenate. No significant difference is observed when compar-
ing ratios of NeuN+ counts to total events quantified by flow
cytometry.
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Table S1 miRNA RT-qPCR validation study results. RT-qPCR
was used to validate the five differentially expressed miRNA in the
same set of sample used for miRNA-sequence analysis. The table
lists the difference and standard error of fold change between
condition (2-DDCt), as well as p-values from two-tailed Welch’s t-
tests, for ten control and eleven Huntington’s disease (HD)
samples.
(DOCX)
Table S2 Sample information for eight Huntington’s disease
brains used for RT-qPCR replication study. Post-mortem intervals
(PMI), RNA integrity numbers (RIN) and ages at death for the
eight Huntington’s disease (HD) brains used for RT-qPCR
verification of the five differentially expressed miRNA.
(DOCX)
Table S3 Sample information for eight control brains used for
RT-qPCR replication study. Post-mortem intervals (PMI), RNA
integrity numbers (RIN) and ages at death for the eight control
brains used for RT-qPCR verification of the five differentially
expressed miRNA.
(DOCX)
Table S4 miRNA RT-qPCR replication study results. RT-
qPCR was used to replicate the five differentially expressed
miRNA in an independent sample set of Huntington’s disease
(HD) brains. The table lists the difference and standard error of
fold change between condition (2-DDCt), as well as p-values from
one-tailed Welch’s t-tests, for eight control and eight Huntington’s
disease samples.
(DOCX)
Table S5 Sample information for fourteen Parkinson’s disease
brains used for RT-qPCR replication study. Post-mortem intervals
(PMI), RNA integrity numbers (RIN) and ages at death for the
fourteen Parkinson’s disease (PD) brains used for RT-qPCR
verification of the five differentially expressed miRNA.
(DOCX)
Table S6 Read statistics for miRNA-sequence analysis. Sum-
mary of Illumina miRNA-sequence read and quality control
statistics generated from the FASTX-toolkit.
(DOCX)
Table S7 Mean and standard deviation inner-distance estimates
for TopHat2 alignment. Statistics used to estimate the distance
between paired-end reads, generated from picardTools.
(DOCX)
Table S8 Read statistics for mRNA-sequence analysis. Summa-
ry of Illumina mRNA-sequence read and quality control statistics
generated from the FASTX-toolkit.
(DOCX)
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